Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06658730 · ClinicalTrials.gov registry record
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
A clinical trial of Vascular Disease and Intramural Hematoma, sponsored by W.L.Gore & Associates.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 10
- Study locations
NCT06658730: Recruiting study of Vascular Disease and Intramural Hematoma, sponsored by W.L.Gore & Associates.
NCT06658730 is a study of Vascular Disease and Intramural Hematoma that is actively recruiting participants, run by W.L.Gore & Associates. The registered enrollment target is 1,500 participants, above the 638-participant average among 9 other Vascular Disease trials with a reported enrollment target (135% higher). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06658730, a study of Vascular Disease and Intramural Hematoma, is actively recruiting participants, sponsored by W.L.Gore & Associates.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 10
- Study locations
Study Summary
An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-market registry for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System (CTAG w/AC) is intended to demonstrate that thoracic endovascular aortic repair (TEVAR) for lesions of the descending thoracic aorta continues to be a suitable treatment option for appropriately selected patients.
Primary Outcome
* Successful access, delivery, and accurate deployment of the device to the intended location, and retrieval of the delivery system. * The absence of any additional corrective procedure related to the device, procedure, or withdrawal of the delivery system. Events will not include interventions at the access site(s), lumbar drains to address spinal cord ischemia, or additional interventions to address non-treatment areas.
Conditions Studied
Interventions
- DEVICE Endovascular
Study Locations (10)
Other
- Rigshospitalet - Copenhagen
- Centre Hospitalier Universitaire Strasbourg - Strasbourg
- Universitatsmedizin Frankfurt - Frankfurt
- Regensburg University Hospital - Regensburg
- Laiko General Hospital of Athens - Athens
- Hospital Universitari de Bellvitge - Barcelona
- Uppsala University - Uppsala
California
- Cedars-Sinai Medical Center - Los Angeles
Indiana
- Indiana University School of Medicine - Indianapolis
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2038-08 |
What NCT06658730 shows while recruiting
NCT06658730 is an observational study that tracks outcomes without assigning an intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 638-participant average among 9 other Vascular Disease trials with a reported enrollment target (135% higher).
The record links to 8 conditions, with Vascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Endovascular is the first listed.
NCT06658730 lists 10 locations in 4 states (Other, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT06658730 about?
NCT06658730 is a clinical study titled "Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance". An observational, prospective multi-regional post-market registry collecting mid- and long-term data to assess outcomes through ten years of follow-up for subjects treated with GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System as a part of routine clinical practice. This post-ma...
What is the current status of trial NCT06658730?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2025-06-19. Estimated completion is 2038-08.
What conditions does trial NCT06658730 study?
This clinical trial studies the following conditions: Vascular Disease, Intramural Hematoma, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta.
What interventions are being tested in trial NCT06658730?
The interventions under investigation include: Endovascular (DEVICE).
Who is sponsoring clinical trial NCT06658730?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06658730 being conducted?
This trial has 10 study locations across California, Indiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06658730's enrollment target sits among peer trials
1,500 2nd of 9 the highest of 9 other Vascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Studies of Neuregulin/ERBB Signaling in Human Heart
RECRUITING
-
Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
COMPLETED · Phase 1
-
Study of Abnormal Blood Clotting in Children With Stroke
COMPLETED
-
Healthy Heart Amputation Rehabilitation Treatment (H.A.R.T)
COMPLETED · Phase 2
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI